Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy.

Author: Yongxian HU ¹ ; Jiasheng WANG ; Chengfei PU ; Kui ZHAO ; Qu CUI ; Guoqing WEI ; Wenjun WU ; Lei XIAO ; Yang XIAO ; Jinping WANG ; Zhao WU ; He HUANG
Author Information

1. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. huanghe@zju.edu.cn
Publication Type:Case Report
Keywords: Refractory/relapse; B-cell lymphoma; Chimeric antigen receptor T cells; Terminal ileal perforation
MeSH: B-Lymphocytes*; Humans; Ileum; Lymphoma, B-Cell*; Receptors, Antigen*; T-Lymphocytes*
From:Cancer Research and Treatment 2018;50(4):1462-1466
CountryRepublic of Korea
Language:English
Abstract: Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.